Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 19, 2021

SELL
$169.75 - $207.73 $7.78 Million - $9.52 Million
-45,822 Closed
0 $0
Q2 2021

Aug 09, 2021

BUY
$128.63 - $176.89 $5.89 Million - $8.11 Million
45,822 New
45,822 $7.77 Million
Q1 2021

May 13, 2021

SELL
$126.83 - $175.69 $601,935 - $833,824
-4,746 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$121.19 - $165.49 $12,603 - $17,210
-104 Reduced 2.14%
4,746 $691,000
Q2 2020

Jul 17, 2020

SELL
$104.21 - $156.44 $3.56 Million - $5.35 Million
-34,187 Reduced 87.58%
4,850 $718,000
Q1 2020

Apr 16, 2020

SELL
$93.12 - $133.99 $1.16 Million - $1.67 Million
-12,447 Reduced 24.18%
39,037 $4.25 Million
Q4 2019

Feb 14, 2020

SELL
$74.51 - $124.23 $3.12 Million - $5.2 Million
-41,885 Reduced 44.86%
51,484 $5.93 Million
Q3 2019

Nov 14, 2019

BUY
$70.9 - $87.82 $1.32 Million - $1.64 Million
18,680 Added 25.01%
93,369 $7.51 Million
Q2 2019

Aug 14, 2019

BUY
$65.86 - $92.79 $432,239 - $608,980
6,563 Added 9.63%
74,689 $5.42 Million
Q1 2019

May 07, 2019

SELL
$72.76 - $93.45 $9.44 Million - $12.1 Million
-129,743 Reduced 65.57%
68,126 $6.37 Million
Q4 2018

Jan 25, 2019

BUY
$62.67 - $88.33 $12 Million - $16.9 Million
191,629 Added 3070.98%
197,869 $14.4 Million
Q3 2018

Oct 30, 2018

SELL
$87.52 - $122.67 $2.62 Million - $3.68 Million
-29,960 Reduced 82.76%
6,240 $546,000
Q2 2018

Aug 03, 2018

BUY
$88.31 - $107.8 $809,272 - $987,879
9,164 Added 33.9%
36,200 $3.57 Million
Q1 2018

Apr 30, 2018

SELL
$115.92 - $148.54 $770,288 - $987,048
-6,645 Reduced 19.73%
27,036 $3.22 Million
Q4 2017

Jan 18, 2018

SELL
$114.49 - $139.98 $5.82 Million - $7.11 Million
-50,820 Reduced 60.14%
33,681 $4.28 Million
Q3 2017

Oct 31, 2017

BUY
$72.53 - $118.27 $6.13 Million - $9.99 Million
84,501
84,501 $9.93 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Frontier Capital Management CO LLC Portfolio

Follow Frontier Capital Management CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frontier Capital Management CO LLC with notifications on news.